Role of PET/CT in the evaluation of cervical cancer

Jover, Raquel; Lourido, Daniel; González, Cristina Aracil; Rojo, Alejandro; Gorospe, Luis; Alfonso, José M.

doi:10.1016/j.ygyno.2008.05.023

Cited by 31 publications

(20 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to these studies the contribution of PET scan to treatment planning seems to be superior to CTscan due to its higher sensitivity for the detection of metastasis [32][33][34]36]. Yet, like CT-scans, the value of a PET scan is limited in the detection of pulmonary micro metastasis [35,37].…”

Section: Discussionmentioning

confidence: 99%

The Role of Chest Computed Tomography in the Work-up of Patients with Cervical or Endometrial Cancer

Demir¹,

Pijnenborg²,

Bekkers³

2011

JCT

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

The Role of Chest Computed Tomography in the Work-up of Patients with Cervical or Endometrial Cancer

Demir¹,

Pijnenborg²,

Bekkers³

2011

JCT

View full text Add to dashboard Cite

show abstract

“…The applications of PET/CT in cervical cancer patients include: assessing metabolic tumor activity and possible endometrial involvement, evaluating pelvic nodal involvement (even in cases with negative CT or MRI studies), detection of distant metastases where it can be used as a first imaging technique, radiation therapy planning of metabolically active lymph nodal lesions, identification of persistent/recurrent disease following neoadjuvant therapy and prognostication in terms of response-survival relationship. [91,92] Many studies have evaluated the role of FDG-PET in primary staging of cervical cancer and showed a variable sensitivity and specificity. [93,94] A recent meta-analysis by Havrilesky et al demonstrated a combined pooled sensitivity and specificity of 84% and 95%, respectively, for aortic node metastases, while similar values for pelvic node metastases were 79% and 99%, respectively.…”

Section: Cervical Cancermentioning

confidence: 99%

Clinical applications of positron emission tomography-computed tomography in oncology

2010

View full text Add to dashboard Cite

Positron emission computed tomography (PET) is a functional diagnostic imaging technique, which can accurately measure in vivo distribution of a variety of radiopharmaceuticals. The ability of PET to study various biological processes (glucose, amino acid, phospholipids, receptors etc.) opens up new possibilities for both day-to-day clinical use and research applications in the practice of oncology. Addition of CT to PET has resulted in better specificity and sensitivity than either of the modalities alone, as the combined approach has the ability to demonstrate functional and structural details in the same setting. F-18 fluoro-2-deoxy-D-glucose (FDG), an analogue of glucose, is the most commonly used radiotracer in PET-CT imaging. The F-18 FDG uptake in tumor cells is directly proportional to glucose metabolism in the cells. Since glucose metabolism is increased several folds in the malignant tumors, PET-CT images show preferential higher FDG uptake in malignant cells as compared to normal cells. F-18 FDG PET-CT has been found to be useful in the initial staging, detection of recurrent disease and monitoring the response to the therapy in malignancies including lung cancer, colorectal cancer, lymphoma, melanoma, esophageal cancer, head and neck cancer, breast cancer.

show abstract

“…PET has demonstrated its utility in the diagnosis of hepatic metastases [115][116][117], detection and staging in lung cancer [118,119], detection and staging in head and neck cancer [120], and detection of nodal involvement in cervical cancer [121]. For diagnosis of hepatic metastases from colorectal, gastric, and esophageal cancers, FDG-PET has proven to be the most sensitive imaging modality compared to ultrasound, CT and MRI [122].…”

Section: Metastasis Detection and Therapy Adjustment By Mri Pet/ct Amentioning

confidence: 99%

“…For the majority of tumors (such as head and neck, NSCLC, cervical cancer), metabolic PET was superior to CT in radiotherapy planning and assessment of therapy response [173]. Several studies have indicated that in responding tumors, FDG uptake markedly decreases within the first chemotherapy [16], [22], [23], [26], [28], [30], [31], [34], [89], [90], [107][108][109][110][111][112], [114][115][116][117][118][119][120][121][122][123] Patient and Treatment Selection [167][168][169][170][171][172][173][174][175][176][177][178][179][180][181], [195,196] DCE-MRI for antivascualr agents Assessment of tumor physiology (perfusion and permeability, Gd-IAUC and AUC, Ktrans, Ve)…”

Section: Changes Of Metabolic Activity By Novel Targeted Agentsmentioning

confidence: 99%

Oncologic Imaging End-Points for the Assessment of Therapy Response

Serkova¹,

Garg²,

Bradshaw‐Pierce³

2009

PRA

View full text Add to dashboard Cite

Sophisticated clinical and diagnostic imaging modalities are critical for the detection, staging, treatment, and follow-up surveillance of cancer. Previously, uni- and bi-dimensional measurements of a tumor lesion were considered the "holy grail" of the assessment of tumor growth and provided imaging end-points for cytotoxic chemotherapeutic agents. With increasing understanding of cancer-related pathways and emerging discoveries of targeted signal transduction inhibitors for cancer treatment, novel pharmacodynamic endpoints of treatment efficacy are required. The innovations in medical imaging include computed tomography (CT), magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS), positron emission tomography (PET), single photon emission tomography (SPECT), ultrasonography (US) and, mostly in the pre-clinical arena, optical imaging. While CT and MRI provide superb anatomic resolution, physiological changes in tumor microenvironment can be assessed by dynamic contrast enhanced MRI (DCE-MRI), metabolic endpoints can be established with PET and MRS protocol, and molecular biomarkers can be non-invasively followed up using PET and MRI-based molecular probes (and optical imaging mostly in pre-clinical setting). Novel protocols for improved spatial resolution, automated quantitative methods for anatomic assessment, and development of physiological, metabolic and molecular imaging probes are currently under investigation. The imaging future promises new avenues for exploration of physiological, metabolic, molecular and genetic events in the human body, performed non-invasively and in real time, using multi-modality imaging platforms. The aim of this article is to represent the available patents on imaging response assessment in oncology.

show abstract

Role of PET/CT in the evaluation of cervical cancer

Cited by 31 publications

References 6 publications

The Role of Chest Computed Tomography in the Work-up of Patients with Cervical or Endometrial Cancer

The Role of Chest Computed Tomography in the Work-up of Patients with Cervical or Endometrial Cancer

Clinical applications of positron emission tomography-computed tomography in oncology

Oncologic Imaging End-Points for the Assessment of Therapy Response

Contact Info

Product

Resources

About